Stop being the product.
Become the owner.
or
sign uplog in
🚨🚨 BREAKING: FIFA President Gianni Infantino finally breaks his silence on the Mbappé vs China controversy.

 Football is a global game, and with that comes a responsibility to respect the people, cultures and countries that make this sport what it is today. China is an important part of the global football community, and I do not believe its concerns should simply be dismissed because this controversy involves one of the biggest footballers in the world.

“At the same time, we must be careful not to turn every disagreement into an international crisis. Kylian Mbappé is a world-class footballer, not a diplomat. If there has been a misunderstanding, then the sensible thing to do is to understand what happened, listen to the concerns being raised and find a reasonable way forward. Nobody benefits when a situation like this continues to escalate.

“However, I will say this: being a global superstar comes with responsibilities. When millions of people look up to you, your actions can have an impact far beyond what you may have intended. I believe Mbappé should understand why this situation has upset some people in China, just as I believe everyone involved should give him a fair opportunity to explain himself. Respect cannot be a one-way street.

“I also believe China deserves to be treated with the same consideration we expect for every other footballing nation. We cannot celebrate the global popularity of football, welcome supporters from every corner of the world and then act surprised when cultural differences lead to disagreements. Chinese supporters matter to this game, and their concerns deserve to be heard. That should never be a controversial position to take.

“But let me be equally clear: FIFA is not here to punish players simply because a situation becomes controversial on social media. Any disciplinary action must have a proper basis under the applicable rules. We must distinguish between a genuine breach of regulations and a disagreement that can be resolved through communication. I would not want football to reach a point where every joke, every photograph or every online interaction becomes a matter for international intervention.

“My advice to Real Madrid and Mbappé would be to approach this situation with maturity. There is nothing wrong with defending your player, but there is also nothing wrong with acknowledging that people elsewhere may have legitimate concerns. If an explanation is needed, provide it. If there has been genuine offence, consider how the situation can be resolved respectfully. That is what responsible leadership looks like.

“And to those in China who feel that their concerns are being ignored, I would say this: you have every right to express your views. But I would encourage everyone to leave room for dialogue rather than allowing this controversy to become a battle between a country and a football club. We must not allow the passion that makes football special to become a reason for division.

“At the end of the day, I do not want to see Mbappé humiliated, and I do not want to see Chinese supporters treated as though their feelings do not matter. Both positions can exist together. Nobody should be above criticism because of their fame, and nobody should be dismissed simply because their reaction is different from ours.

“Football has always been at its best when it brings people together despite their differences. We should be working towards a resolution, not competing to see who can make the loudest statement. China deserves respect, Mbappé deserves fairness, and everyone involved has a responsibility to ensure that this situation does not become bigger than it needs to be.”

🇨🇳🇫🇷 FIFA calls for respect, fairness and dialogue as the Mbappé-China controversy continues.
#earn_millix #FIFA #MBAPPÉ #CHINA #DIPLOMACY #TANGLED #FOOTBALL
show more
#poetryforchange
#earn_millix #philosophymatters #morning
In the break of light, the darkness yields,
A quiet warmth across the fields.
The morning breathes, the shadows fade,
In golden light, a new world made.
The birds sing out, the sky awakes,
With every breath the morning takes.
A blank clean page, a rising sun—
A fresh new day has just begun.

Iam Adekanmi
show more
#Healthcare
#earn_millix
#Update

The U.S. Food and Drug Administration today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. Hibsago is approved for certain adults without cirrhosis who have been taking HBV antiviral therapy for at least six months, have suppressed levels of HBV in their blood and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less, as determined by an FDA-authorized test. 
“For many people living with chronic hepatitis B, treatment can mean taking antiviral medication for years to keep the virus suppressed,”  said Wendy Carter, DO, Acting Director of the Office of Infectious Diseases in the Center for Drug Evaluation and Research . “Hibsago provides a new treatment approach that gives some patients the possibility of maintaining control of the virus after all chronic HBV treatment has ended. This approval represents an important advance for people living with this serious disease.”
Chronic hepatitis B is a long-term liver infection caused by HBV. Over time, the infection can lead to serious liver disease, including cirrhosis, and increase the risk of liver cancer. Hibsago works by targeting the genetic instructions the virus uses to make copies of itself and viral proteins, helping reduce the amount of virus and hepatitis B surface antigen in the body.
The FDA also authorized the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic device to aid in the selection of patients with chronic HBV infection for treatment with antiviral therapy in accordance with the FDA approved drug labeling and to assist in monitoring patients throughout the course of treatment. 
Researchers studied Hibsago in two clinical trials that compared it with a placebo, an inactive treatment. Hibsago is injected under the skin for up to 24 weeks. Patients take it alongside their existing hepatitis B medicine and continue that medicine for at least 24 weeks after their last Hibsago injection. Some patients may then be able to stop their existing medicine if they meet certain health and lab test requirements.
Across the two trials, 24% of patients who received Hibsago met the requirements to stop their existing medicine, compared with none who received placebo. Twenty-four weeks after stopping all hepatitis B treatment, 19% of patients who received Hibsago still had the virus under control, and a protein that signals hepatitis B infection (HBsAg) could not be detected in their blood. 
Hibsago has a boxed warning for serious liver reactions as well as low platelet counts, which can increase the risk of potentially life-threatening bleeding. Hibsago also has warnings for worsening kidney function, serious inflammatory adverse reactions like vasculitis, and serious risks if the injection is not administered properly. Patients need regular blood tests and follow up with their healthcare provider before and during treatment to monitor these risks. The most common side effects, excluding laboratory abnormalities, are injection site reactions, fever, fatigue and headache. 
The FDA granted Hibsago  Fast Track  and  Breakthrough Therapy  designations as well as  Priority Review . The approval was granted to GSK plc. 
show more